Citations

Showing 10 of 108119 citations.

Interim analysis of a phase II trial of nab-paclitaxel in patients with very advanced relapsed/refractory multiple myeloma (RR-MM).
Stewart, A. Keith, Mayo, Angela, Chesi, Marta , Rosenthal, Allison , Fonseca, Rafaël , Mıkhael, Joseph , Kosiorek, Heidi , Bergsagel, P. Leif

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e19537-e19537

10.1200/jco.2015.33.15_suppl.e19537 Get It

Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics.
Keefe, Dorothy Mary Kate, Giri, Nagdeep , Reisman, Arlene, Sbar, Eric, Gernhardt, Diana, Jatoi, Aminah , Lacouture, Mario E. , Sonis, Stephen T. , Wang, Tao

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e19049-e19049

10.1200/jco.2015.33.15_suppl.e19049 Get It

ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.
Oxnard, Geoffrey R. , Mandrekar, Sumithra J. , Malik, Shakun , Mooney, Margaret , Abrams, Jeffrey S. , Jänne, Pasi A. , Gerber, David E. , Dahlberg, Suzanne E. , Li, Tianhong , Ramalingam, Suresh S. , Vokes, Everett E. , Govindan, Ramaswamy

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS7583-TPS7583

10.1200/jco.2015.33.15_suppl.tps7583 Get It

Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
Silverman, Lewis R. , Fenaux, Pierre , Al‐Kali, Aref , Baer, Maria R. , Scott, Bart L. , Greenberg, Peter L. , Kreuzer, Karl Anton, Collins, Robert H. , Azarnia, N., Garcia‐Manero, Guillermo , Sekeres, Mikkael A. , Roboz, Gail J. , Gaïdano, Gianluca , Platzbecker, Uwe , Steensma, David P. , Kreuzer, Karl‐Anton, Godley, Lucy A. , Atallah, Ehab

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7092-7092

10.1200/jco.2015.33.15_suppl.7092 Get It

Case series of hypomethylating agents (HMA) effect on myelodysplastic/myeloproliferative neoplasm unclassified (MDS/MPN-U): Mayo Clinic experience.
Hussein, Ahmed Kamel Abou, Patnaik, Mrinal M. , Zblewski, Darci, Gangat, Naseema , Hashmi, Shahrukh K. , Elliott, Michelle A. , Litzow, Mark R. , Al‐Kali, Aref , Hogan, William J.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7088-7088

10.1200/jco.2015.33.15_suppl.7088 Get It

Effect of grade (G) 3 fibrosis on clinical outcome of patients (Pts) with myelodysplastic syndromes (MDS): Mayo Clinic Experience.
Cheema, Naveed, Baidoun, Firas , Zblewski, Darci, Hashmi, Shahrukh K. , Gangat, Naseema , Wolanskyj, Alexandra P., Litzow, Mark R. , Chen, Dong, Al‐Kali, Aref , Cheema, Naveed, Hogan, William J. , Chen, Dong, Baidoun, Firas

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7085-7085

10.1200/jco.2015.33.15_suppl.7085 Get It

Prognostic impact of renal insufficiency (RI) at diagnosis in patients with chronic lymphocytic leukemia (CLL).
Chaffee, Kari G. , Achenbach, Sara J., Schwager, Susan M., Call, Timothy G. , Strati, Paolo , Slager, Susan L. , Leung, Nelson , Shanafelt, Tait D.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7084-7084

10.1200/jco.2015.33.15_suppl.7084 Get It

A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab (AL) in the early treatment of patients (Pts) with high risk chronic lymphocytic leukemia (CLL).
Bose, Nandita , LaPlant, Betsy, Ottoson, Nadine, Leonardo, Steven , Jonas, Adria, Huhn, Richard D. , Braun, Ada, Ansell, Stephen M. , Zent, Clive S. , Weiner, George J. , Jonas, Adria Bykowski

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7078-7078

10.1200/jco.2015.33.15_suppl.7078 Get It

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
Gojo, Ivana , Patnaik, Mrinal M. , Minden, Mark D. , Levonas, Amy, Fancourt, Craig, Meister, Amy, Kemp, Ramon K., Knox, Clayton D., Rose, Shelonitda, Patel, Payal Shah, Ravandi, Farhad , Kantarjian, Hagop M. , Lam, Raymond, Jones, Mary Elizabeth , Patel, Payal Shah, Tibes, Raoul

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7070-7070

10.1200/jco.2015.33.15_suppl.7070 Get It